Atherosclerotic occlusive disease (ASO) of the lower extremities is primarily caused by atherosclerosis of the lower extremities and is characterized by a state of reduced limb perfusion and metabolic disorders. Despite hemodialysis and medical care for the disease, many patients with ASO are at risk for recurrence, progression to severe limb ischemia, and increased rates of amputation in the patients. Remnant cholesterol (RC) is a strong predictor of ASO development and has been classified as a new atherosclerosis risk factor by the American Heart Association. RC induces endothelial dysfunction, stimulates inflammation and prothrombosis, and accelerates atherosclerosis formation, thereby promoting ASO development. This review summarizes the relevant definitions and detection methods of RC, the relationship between RC and ASO, and treatment methods. However, the definition and detection standard are still controversial. Further clarification of the correlation between RC levels and the occurrence and severity of ASO will provide some guidance for clinical diagnosis and treatment.

Wang Zhenze, Liu Fende, Li Wujun. Research Progress of Remnant Cholesterol in Atherosclerotic Occlusive Disease. Frontiers in Medical Science Research (2024), Vol. 6, Issue 8: 43-46. https://doi.org/10.25236/FMSR.2024.060806.

[1] POLONSKY T S, MCDERMOTT M M. Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia: A Review [J]. Jama, 2021, 325(21): 2188-98.

[2] FOWKES F G, ABOYANS V, FOWKES F J, et al. Peripheral artery disease: epidemiology and global perspectives [J]. Nature reviews Cardiology, 2017, 14(3): 156-70.

[3] STüRZEBECHER P E, KATZMANN J L, LAUFS U. What is ‘remnant cholesterol’? [J]. European Heart Journal, 2023, 44(16): 1446-8.

[4] CHAPMAN M J, GINSBERG H N, AMARENCO P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management [J]. European heart journal, 2011, 32(11): 1345-61.

[5] PIRILLO A, CATAPANO A L. Remnant cholesterol: A reliable prognostic marker? [J]. European journal of preventive cardiology, 2023.

[6] TYBJAERG-HANSEN A, NORDESTGAARD B G, GERDES L U, et al. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis [J]. Atherosclerosis, 1993, 100(2): 157-69.

[7] CHEN X, LI L H. Remnant Cholesterol, a Valuable Biomarker for Assessing Arteriosclerosis and Cardiovascular Risk: A Systematic Review [J]. Cureus, 2023, 15(8): e44202.

[8] SONG Y, ZHAO Y, BAI X, et al. Remnant cholesterol is independently asssociated with an increased risk of peripheral artery disease in type 2 diabetic patients [J]. Frontiers in endocrinology, 2023, 14: 1111152.

[9] GUAN B, WANG A, XU H. Causal associations of remnant cholesterol with cardiometabolic diseases and risk factors: a mendelian randomization analysis [J]. Cardiovascular diabetology, 2023, 22(1): 207.

[10] WADSTRöM B N, WULFF A B, PEDERSEN K M, et al. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study [J]. European heart journal, 2022, 43(34): 3258-69.

[11] BALLING M, NORDESTGAARD B G, LANGSTED A, et al. Small Dense Low-Density Lipoprotein Cholesterol Predicts Atherosclerotic Cardiovascular Disease in the Copenhagen General Population Study [J]. Journal of the American College of Cardiology, 2020, 75(22): 2873-5.

[12] ZHANG S H, REDDICK R L, PIEDRAHITA J A, et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E [J]. Science (New York, NY), 1992, 258(5081): 468-71.

[13] DO R, WILLER C J, SCHMIDT E M, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease [J]. Nature genetics, 2013, 45(11): 1345-52.

[14] VEKIC J, STROMSNES K, MAZZALAI S, et al. Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk [J]. Biomedicines, 2023, 11(11).

[15] OOI E M, BARRETT P H, CHAN D C, et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor [J]. Clinical science (London, England : 1979), 2008, 114(10): 611-24.

[16] PENG J, LUO F, RUAN G, et al. Hypertriglyceridemia and atherosclerosis [J]. Lipids in health and disease, 2017, 16(1): 233.

[17] POLEDNICZEK M, NEUMAYER C, KOPP C W, et al. Micro- and Macrovascular Effects of Inflammation in Peripheral Artery Disease-Pathophysiology and Translational Therapeutic Approaches [J]. Biomedicines, 2023, 11(8).

[18] SHAYA G E, LEUCKER T M, JONES S R, et al. Coronary heart disease risk: Low-density lipoprotein and beyond [J]. Trends in cardiovascular medicine, 2022, 32(4): 181-94.

[19] NORDESTGAARD B G. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology [J]. Circulation research, 2016, 118(4): 547-63.

[20] GUGLIUCCI A. Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux [J]. Journal of clinical medicine, 2023, 12(13).

[21] SILBERNAGEL G, SCHARNAGL H, KLEBER M E, et al. LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study [J]. Atherosclerosis, 2019, 282: 37-44.

[22] YANAI H, ADACHI H, HAKOSHIMA M, et al. Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments [J]. International journal of molecular sciences, 2023, 24(18).

[23] HAO Q Y, GAO J W, YUAN Z M, et al. Remnant Cholesterol and the Risk of Coronary Artery Calcium Progression: Insights From the CARDIA and MESA Study [J]. Circulation Cardiovascular imaging, 2022, 15(7): e014116.

[24] YAMASHITA S, ARAI H, YOKOTE K, et al. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination [J]. International journal of molecular sciences, 2019, 20(22).

[25] DAS PRADHAN A, GLYNN R J, FRUCHART J C, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk [J]. The New England journal of medicine, 2022, 387(21): 1923-34.

[26] CRIQUI M H, ABOYANS V. Epidemiology of Peripheral Artery Disease [J]. Circulation Research, 2015, 116(9): 1509-26.